CAICaris Life Sciences, Inc.
Price
-9.0%1YEnd-of-day closes, not the intraday tick.
Great business, demanding price
Quality strong, nothing alarming, demanding price, growth steady, the market undecided.
We are a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer. We develop and commercialize innovative solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Our entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets.
In the company’s own words · 10-K filed Mar 3, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Caris Life Sciences, Inc. (CAI) reported revenue of $264M in Q2 2026 (quarter ended Jun 30, 2026), up 45% from the same quarter a year earlier. That came with net loss of $637K. For the full year FY2025, revenue was $812M (+97% year on year) and net income −$68M. Its largest product in Q2 2026 was Molecular Profiling Services at $252M, 96% of the disclosed total, well ahead of Pharma Research And Development Services at 4.3%. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 5, 2026Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance.Earnings release · press release
- May 7, 2026Caris Life Sciences Reports First Quarter 2026 Financial Results.Earnings release · press release
- Apr 2, 2026On April 1, 2026 (the “Closing Date”), Caris Life Sciences, Inc., a Texas corporation (the “Company”) entered into a Financing Agreement, dated as of the Closing Date (the “New Credit Agreement”), by and among the Company, as borrower, certain subsidiaries of the Company, as guarantors, the lenders from time to time …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $263.7MThe company’s own SEC segment disclosure.
- Molecular Profiling Services$252.3M96%
- Pharma Research And Development Services$11.5M4%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Biotechnology
The closest names by size in the same industry